Vyome Holdings Inc HIND

$1.20 -0.25 (-17.24%)

Valuation

Market cap
8,422,000
Revenue TTM
$320,000
Net income TTM
$-10,260,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-3,206.25%
Debt to equity
0.05

Trading

Volume
35,000
Avg volume
15,956
Day's range
$1.20 – $1.43
Shares out
7,018,000
Stochastic %K
0%
Beta
1.51
Analysts
Strong Buy
Price target
$8.83

Price

Company profile

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treat...

Show more

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
973 832 8147
Website
https://www.vyometx.com
Address
Harvard Square, One Mifflin Place Suite 400, Cambridge, United States

Latest news

No headlines yet.